Viatris’ Insulin Aspart Endorsed By EMA

Kixelle Biosimilar Rival To NovoRapid Receives CHMP Positive Opinion

Viatris has received a positive opinion from the EMA’s CHMP recommending granting a pan-European marketing authorization for the firm’s insulin aspart biosimilar rival to NovoRapid.

NovoRapid
The EMA has endorsed Viatris’ biosimilar version of NovoRapid • Source: Shutterstock

Viatris should receive a pan-European marketing authorization for its Kixelle (insulin aspart) biosimilar rival to NovoRapid, the Committee for Medicinal Products for Human Use within the European Medicines Agency has recommended in a positive opinion.

The European Commission typically acts on the CHMP’s

More from Products

More from Generics Bulletin

Trump Order On Domestic Manufacturing Wins Plaudits From Industry

 
• By 

An executive order from US president Donald Trump aimed at incentivizing domestic manufacturing of critical medicines has been welcomed by the US Association for Accessible Medicines.

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By 

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By 

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.